Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Souers

Showing results (211-220 of 248) with videos related to

Pageof 25
Sort By:
American Journal of Hematology|November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapyRelja Popovic, Fengjiao Dunbar, Charles Lu, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Structure-Based Design of A-1293102, a Potent and Selective BCL-X<sub>L</sub> InhibitorZhi-Fu Tao, Xilu Wang, Jun Chen, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesityAndrew J Souers, Ju Gao, Dariusz Wodka, et al.
Cancers|June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXACarter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
European Journal of Pharmacology|June 13, 2006
Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxietyAna M Basso, Natalie A Bratcher, Kelly B Gallagher, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Molecular Cancer Therapeutics|June 5, 2021
Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified NeuroblastomaKrista M Dalton, Kateryna Krytska, Timothy L Lochmann, et al.
The Journal of Organic Chemistry|November 1, 2023
Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467Patrick B Brady, Bryan K Sorensen, Roberto M Risi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2018
The Ewing Family of Tumors Relies on BCL-2 and BCL-X<sub>L</sub> to Escape PARP Inhibitor ToxicityDaniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Respiratory Cytology--Current Trends Including Endobronchial Ultrasound-Guided Biopsy and Electromagnetic Navigational Bronchoscopy: Analysis of Data From a 2013 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic CytologyCharles D Sturgis, Carrie B Marshall, Guliz A Barkan, et al.
Pageof 25

Showing results (211-220 of 248) with videos related to

Sort By:
Pageof 25
American Journal of Hematology|November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapyRelja Popovic, Fengjiao Dunbar, Charles Lu, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Structure-Based Design of A-1293102, a Potent and Selective BCL-X<sub>L</sub> InhibitorZhi-Fu Tao, Xilu Wang, Jun Chen, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesityAndrew J Souers, Ju Gao, Dariusz Wodka, et al.
Cancers|June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXACarter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
European Journal of Pharmacology|June 13, 2006
Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxietyAna M Basso, Natalie A Bratcher, Kelly B Gallagher, et al.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.
Molecular Cancer Therapeutics|June 5, 2021
Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified NeuroblastomaKrista M Dalton, Kateryna Krytska, Timothy L Lochmann, et al.
The Journal of Organic Chemistry|November 1, 2023
Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467Patrick B Brady, Bryan K Sorensen, Roberto M Risi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2018
The Ewing Family of Tumors Relies on BCL-2 and BCL-X<sub>L</sub> to Escape PARP Inhibitor ToxicityDaniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Respiratory Cytology--Current Trends Including Endobronchial Ultrasound-Guided Biopsy and Electromagnetic Navigational Bronchoscopy: Analysis of Data From a 2013 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic CytologyCharles D Sturgis, Carrie B Marshall, Guliz A Barkan, et al.
Pageof 25